<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336812">
  <stage>Registered</stage>
  <submitdate>13/04/2011</submitdate>
  <approvaldate>18/04/2011</approvaldate>
  <actrnumber>ACTRN12611000401954</actrnumber>
  <trial_identification>
    <studytitle>Does using progesterone reduce the miscarriage rate in high risk pregnancies?</studytitle>
    <scientifictitle>In pregnant women with previous subfertility, does progesterone supplementation decrease the likelihood of miscarriage?</scientifictitle>
    <utrn>U1111-1120-7674</utrn>
    <trialacronym>Pregnancy Maintenance Trial (PMTrial)</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Miscarriage</healthcondition>
    <healthcondition>Subfertility</healthcondition>
    <healthcondition>Recurrent miscarriage</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Progesterone pessary 400 mg, nightly until 12 weeks and 0 days, must be recruited prior to 7 weeks.</interventions>
    <comparator>Placebo pessary, carrier compound of the intervention pessary, identical in appearance.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Miscarriage</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Live birth</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gestation at Birth</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Birth weight</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Threatened miscarriage, presentation to medical facility with bleeding and/or pain prior to 20 weeks gestation.</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Congenital anomaly</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Antepartum haemorrhage, presentation to medical facility with bleeding in pregnancy after 20 weeks gestation. Approximate volume will be recorded.</outcome>
      <timepoint>Completion of index pregnancy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Previously diagnosed with subfertility (no pregnancy after 12 months random unprotected intercourse, a history of 3 or more miscarriages, failing to achieve an ongoing pregnancy after 12 months of random unprotected intercourse)
2. Pregnancy less than 7 weeks + 0 days</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Women who are pregnant as a result of Assisted Reproductive Technologies</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Informed, meet criteria, consented, enrolled, 'script' given, dispensed as blinded therapy at pharmacy according to randomisation schedule</concealment>
    <sequence>Computer-generated variable block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>27/01/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>344</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Luke McLindon</primarysponsorname>
    <primarysponsoraddress>Mater Mothers' Hospital
Raymond Terrace
South Brisbane
Queensland  4101</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Mater Mothers' Hospital</fundingname>
      <fundingaddress>Mater Health Services
Raymond Terrace
South Brisbane
Queensland 4101</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Mater Mothers' Hospital</sponsorname>
      <sponsoraddress>Raymond Terrace
South Brisbane
Queensland   4101</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project will assess the effect of progesterone therapy on pregnancy outcomes in women previously diagnosed with subfertility.
It is hypothesised that progesterone supplementation in early pregnancy decreases the likelihood of miscarriage, and potentially late pregnancy complications in women with previous subfertility.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mater Health Services Human Research Ethics Committee</ethicname>
      <ethicaddress>Mater Health Services
Stanley St
South Brisbane
Queensland  4101</ethicaddress>
      <ethicapprovaldate>12/01/2012</ethicapprovaldate>
      <hrec>EC00332</hrec>
      <ethicsubmitdate>14/04/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Luke McLindon</name>
      <address>Mater Mothers' Hospital
Raymond Terrace
South Brisbane
Queensland  4101</address>
      <phone>61 7 3163 8111</phone>
      <fax />
      <email>lucas.mclindon@mater.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Chris Riley, RM</name>
      <address>Fertility Assessment and Research Clinic
Mater Mothers' Hospital
Raymond Terrace
South Brisbane
Queensland  4101</address>
      <phone>61 7 3163 8437</phone>
      <fax>61 7 3163 2137</fax>
      <email>naturalfertility@mater.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Luke McLindon</name>
      <address>Mater Health Services
Raymond Terrace
South Brisbane
Queensland 4101</address>
      <phone>61 7 3163 8111</phone>
      <fax />
      <email>lucas.mclindon@mater.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>